The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients
Not Applicable
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000009711
- Lead Sponsor
- Kyushu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation (ascites, bleeding varices, or encephalopathy); (3) other causes of liver disease (autoimmune hepatitis, primary biliary cirrhosis, or steatohepatitis); (4) excessive active alcohol consumption (a daily intake of more than 40 g of ethanol) or drug abuse; (5) suspected HCC at entry; or (6) treatment with antiviral or immunosuppressive agents prior to enrollment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TVR-based triple therapy can be used successfully and safely to treat elderly patients with genotype 1 chronic hepatitis C.
- Secondary Outcome Measures
Name Time Method